Aortic Valve Stenosis Clinical Trial
Official title:
Clinical Value of Stress Echocardiography in Moderate Aortic Stenosis
The management of symptomatic patients with moderate Aortic Stenosis (AS) remains challenging and tests that would give more definitive answers are needed. The value of increase in Aortic Valve mean Gradient (AVMG), lack of change in Aortic Valve area (AVA) and calculation of valve compliance/resistance during stress echo (SE) in the symptomatic moderate AS population prognostication has to the investigators knowledge not been examined before. Similarly the additive value of myocardial blood flow reserve (MBFR), Computed Tomography (CT) calcium score, speckle tracking echocardiography, carotid ultrasonography, and N-Terminal pro B- type natriuretic peptide B (NT-proBNP) in the prognostication of this population group especially in combination with SE remains unclear.
The prevalence of aortic valve stenosis (AS) has increased over the last few decades due to
improvement in life expectancy and a growing elderly population. A wealth of data is
available on patients with severe AS, whereas the risk stratification and management of
patients with symptomatic moderate AS remains contentious.
Stress echocardiography (SE) is a recognised tool for the risk stratification of patients
with asymptomatic severe AS. Exercise is the preferred mode of stress in this group, as it
provides important prognostic information- such as presence of symptoms, overall exercise
capacity and precipitation of hypotension. Significant increase in mean gradient (MG) (MG
>20mmHg) is an independent predictor of valve intervention or cardiovascular death, similar
to older age, diabetes and high resting gradient and this is recognised in international
guidelines as a parameter to risk stratify asymptomatic severe AS. The increase in MG in the
context of increasing transvalvular flow during exercise is usually accompanied by little or
no change in aortic valve area (AVA). Thus, mechanistically, the increase in MG is associated
with worse outcome because it reflects the intrinsic non-compliance of the aortic valve and
hence resistance. A compliant valve will open to accommodate the increased flow during
stress, whereas a fixed valve orifice will not, resulting in increased gradients. It is
therefore advised that these patients with asymptomatic severe AS and significant increase in
MG during exercise may be reasonably considered for aortic valve intervention.
In moderate AS current guidelines recommend Aortic Valve replacement (AVR) only when other
cardiac surgery (coronary artery bypass grafting) is planned (class IIa). This is because
patients with moderate AS are a heterogeneous group with regard to the risk of adverse
events: some have indeed rapid progression to severe AS, and/or Left Ventricular (LV)
dysfunction and cardiovascular death, whereas others remain stable for many years. Overall
moderate AS carries a substantial risk of death or valve intervention, with the estimated
likelihood of event free survival at 4 years being 55-60%. Furthermore the presence of
symptoms increases the overall likelihood of risk in moderate AS, as there is a significant
difference in outcome between minimally symptomatic and symptomatic moderate AS. It maybe
hypothesised that patients with moderate AS and symptoms in the absence of myocardial
ischaemia due to flow-limiting coronary artery disease likely has the same valve hemodynamics
as one with severe AS, particularly decreased valve compliance/increased resistance. These
characteristics are likely to manifest during exercise when transvalvular flow is increased
resulting in significant increase in gradient with little change in AVA. Accordingly, resting
AVA and MG may not be the best parameters for determining suitability for valve intervention,
particularly as the overall mortality of symptomatic moderate aortic stenosis approaches that
of symptomatic severe AS. However, clear criteria that risk-stratify patients with
symptomatic moderate AS and guide timing for intervention do not currently exist.
Accordingly the role of SE could be expanded beyond assessment of risk in asymptomatic severe
AS to improve risk stratification in patients with symptomatic moderate AS. This is on the
assumption that moderate AS associated with symptoms of breathlessness, chest pain or syncope
is likely to have the same characteristics as severe AS. This means that during SE in
moderate symptomatic AS one would expect the AVA to remain unchanged, the valve resistance to
be elevated and the MG to increase.
Furthermore during SE apart from valve related indices that determine severity (AVA, MG),
myocardial blood flow reserve (MBFR) has been shown to correlate with severity of AS; reduced
MBFR is seen in severe AS whereas MBFR<1.8 has an accuracy of 85% for distinguishing severe
from non-severe AS. It could therefore be that MBFR can also contribute in the risk
stratification of symptomatic moderate AS.
It has been suggested that several other tests could contribute to the risk stratification of
AS i.e. CT calcium score, speckle tracking echocardiography, carotid ultrasonography, and
N-terminal pro-brain natriuretic peptide (NT-proBNP). Specifically it has been shown that
aortic valve calcium score correlates with AS severity and that there is moderate agreement
between AVA as defined by American College of Cardiology (ACC) guidelines and the degree of
AS determined from AV calcium score. Basal and global longitudinal strain (GLS) have been
found to be independently associated both with the severity of AS and the presence of
symptoms. Furthermore GLS can predict all-cause mortality in patients with AS and could
therefore improve the identification of the optimal timing for AV replacement. The severity
of AS in general has also been shown to correspond to an increase of carotid plaque and
intima media thickness (IMT). Finally NT-proBNP values correlate with the severity of AS and
in moderate AS, NT-proBNP can differentiate between symptomatic and asymptomatic status.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03186339 -
Validation of the "TASQ" in Patients Undergoing SAVR or TF-TAVI
|
||
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Terminated |
NCT02854319 -
REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System
|
N/A | |
Recruiting |
NCT05601453 -
The ReTAVI Prospective Observational Registry
|
||
Withdrawn |
NCT05481814 -
CPX in Paradoxical Low Flow Aortic Stenosis
|
||
Completed |
NCT02241109 -
Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity
|
N/A | |
Completed |
NCT01700439 -
Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve
|
N/A | |
Recruiting |
NCT04429035 -
SLOW-Slower Progress of caLcificatiOn With Vitamin K2
|
N/A | |
Completed |
NCT04103931 -
Impact of a Patient Decision Aid for Treatment of Aortic Stenosis
|
N/A | |
Completed |
NCT03950440 -
Assessing the Incidence of Postoperative Delirium Following Aortic Valve Replacement
|
||
Active, not recruiting |
NCT02661451 -
Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)
|
N/A | |
Completed |
NCT02847546 -
Evaluation of the BARD® True™ Flow Valvuloplasty Perfusion Catheter for Aortic Valve Dilatation
|
N/A | |
Completed |
NCT02758964 -
Evaluation of Cerebral Thrombembolism After TAVR
|
||
Not yet recruiting |
NCT02541877 -
Sizing-sTrategy of Bicuspid AoRtic Valve Stenosis With Transcatheter Self-expandable Valve
|
Phase 3 | |
Not yet recruiting |
NCT02536703 -
Safety and Efficacy of Lotus Valve For TAVI In Patients With Severe Aortic Stenosis In Chinese Population
|
Phase 3 | |
Not yet recruiting |
NCT02221921 -
Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI
|
N/A | |
Completed |
NCT02249000 -
BIOVALVE - I / II Clincial Investigation
|
N/A | |
Active, not recruiting |
NCT02080299 -
Protection by Remote Ischemic Preconditioning During Transcatheter Aortic Valve Implantation
|
Phase 2 | |
Terminated |
NCT01939678 -
Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease
|
||
Recruiting |
NCT01683474 -
Safety and Performance of TAVI of Venus MedTech Aortic Valve Prosthesis
|
N/A |